Get the Stockscreener App
1.685
0.88%
-0.015
Essa Pharma Inc stock is traded at $1.685, with a volume of 84,056.
It is down -0.88% in the last 24 hours and down -10.85% over the past month.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
See More
Previous Close:
$1.70
Open:
$1.71
24h Volume:
84,056
Relative Volume:
0.09
Market Cap:
$75.46M
Revenue:
-
Net Income/Loss:
$-28.54M
P/E Ratio:
-2.6328
EPS:
-0.64
Net Cash Flow:
$-22.72M
1W Performance:
-2.03%
1M Performance:
-10.85%
6M Performance:
-62.97%
1Y Performance:
-84.18%
1-Day Range:
$1.685
$1.72
1-Week Range:
$1.67
$1.73
52-Week Range:
$1.40
$10.97
Essa Pharma Inc Stock (EPIX) Company Profile
Name
Essa Pharma Inc
Sector
Industry
Phone
(778) 331-0962
Address
SUITE 720, VANCOUVER, BC
Compare EPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPIX
Essa Pharma Inc
|
1.685 | 75.46M | 0 | -28.54M | -22.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.76 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.34 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.96 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-04-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-04-21 | Initiated | Piper Sandler | Overweight |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-25-19 | Initiated | Oppenheimer | Outperform |
View All
Essa Pharma Inc Stock (EPIX) Latest News
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma - PR Newswire
Class Action Filed Against ESSA Pharma Inc. (EPIX)March 25, 2025 Deadline to JoinContact The Gross Law Firm - Marketscreener.com
ROSEN, A LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before - The Bakersfield Californian
Shareholder Rights Law Firm Robbins LLP Urges EPIX Shareholders with Large Losses to Seek Counsel for the ESSA Pharma Inc. Class Action - PR Newswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain OfficersEPIX - PR Newswire
Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma - GlobeNewswire
IMPORTANT NOTICE: IF YOUR FINANCIAL ADVISOR RECOMMENDED ESSA PHARMA INVESTMENTS PLEASE CONTACT KT LAW - EIN News
ESSA Pharma (EPIX) Projected to Post Earnings on Tuesday - MarketBeat
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
ESSA Pharma Inc. (NASDAQ:EPIX) Short Interest Down 5.3% in January - MarketBeat
EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securit - GuruFocus.com
EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit - Finansavisen
EPIX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
March 25, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against EPIX - PR Newswire
Indo-Asian News Service - IANS India Pvt Ltd
ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of ESSA Pharma Inc.(EPIX) Shareholders - PR Newswire
Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Shareholders of ESSA Pharma Inc. Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your RightsEPIX - PR Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
EPIX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
ESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
EPIX Investor Notice: Shareholder Rights Law Firm Robbins - GlobeNewswire
EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
Stockholder Alert: Robbins LLP Informs Investors of the ESS Pharma Inc. Class Action - cnhinews.com
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
ESSA Pharma Misled Investors Over Cancer Treatment, Lawsuit Says - Bloomberg Law
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ESSA Pharma Inc. (EPIX) - EIN News
Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Short Interest in ESSA Pharma Inc. (NASDAQ:EPIX) Declines By 5.3% - MarketBeat
ESSA Pharma (NASDAQ:EPIX) Share Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
3 Promising US Penny Stocks With Market Caps Under $80M - Simply Wall St
ESSA Pharma Inc. (NASDAQ:EPIX) Sees Significant Growth in Short Interest - MarketBeat
ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Below 50 Day Moving Average – What’s Next? - Defense World
ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Essa Pharma Inc Stock (EPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Essa Pharma Inc Stock (EPIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Virsik Peter | Chief Operating Officer |
Oct 07 '24 |
Sale |
6.03 |
694 |
4,185 |
7,776 |
| Virsik Peter | Chief Operating Officer |
Sep 09 '24 |
Sale |
6.00 |
694 |
4,164 |
8,470 |
| Virsik Peter | Chief Operating Officer |
Sep 03 '24 |
Sale |
6.03 |
2,082 |
12,554 |
9,164 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):